Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 1;34(4):598-603.
doi: 10.1097/WCO.0000000000000960.

Stopping disease-modifying therapy in relapsing and progressive multiple sclerosis

Hans-Peter Hartung  1   2   3 , Sven G Meuth  1 , Deborah M Miller  4 , Giancarlo Comi  5
Affiliations
Review

Stopping disease-modifying therapy in relapsing and progressive multiple sclerosis

Hans-Peter Hartung et al. Curr Opin Neurol. .

Abstract

Purpose of review: To assess the reasons for considering discontinuation of disease-modifying therapies (DMTs)in patients with multiple sclerosis (MS). Relevant aspects of the natural history, pathology, and immunology are analyzed.

Recent findings: A number of retrospective observational studies in aggregate indicate that stopping DMTs may be attempted in older individuals with stable disease. Prognostic factors have been identified informing about the risk of recurrence of disease activity after DMT discontinuation.

Summary: Several clinical scenarios provide a rationale to stop DMTs in people with MS. Cumulative evidence has been gathered recently allowing us to more precisely weigh the risks against the benefits. This information aids in the decision process.

Trial registration: ClinicalTrials.gov NCT03073603.

PubMed Disclaimer

References

    1. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. New Engl J Med 2018; 378:169–180.
    1. Tintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis – success from bench to bedside. Nat Rev Neurol 2018; 15:53–57.
    1. Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. Am J Med 2020; 133:1380–1390.
    1. McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA Neurol 2021; 325:765–779.
    1. Derfuss T, Mehling M, Papadopoulos A, et al. Advances in oral immunomodulating therapies in relapsing multiple sclerosis. Lancet Neurol 2020; 19:336–347.

Associated data